Flu-v Influenza Description 2022
FLU-v is a novel peptide vaccine candidate.
FLU-v is designed to prompt a response not by antibodies but by a separate arm of the immune system—cellular immunity. Cellular immune responses include activity by white blood cells called cytotoxic T lymphocytes (CTLs). Recent research has shown that influenza-specific CTLs can seek out and remove virus-infected cells before and after flu symptoms arise.
The FLU-v vaccine is designed to stimulate the production of these flu-specific CTLs by targeting several proteins inside the virus that do not vary much from strain to strain, meaning that CTL responses against them may be effective against many virus strains.
Flu-v is a synthetic universal flu vaccine candidate offering long-lasting protection across a broad spectrum of influenza viruses.
Flu-v is administered as a subcutaneous injection in the upper arm.
Flu-v News 2010 - 2022
April 8, 2022 - The CDC FluView report estimates that, so far this season, there have been at least 3.8 million flu illnesses, 38,000 hospitalizations, and 2,300 deaths from flu.
March 13, 2020 - Nature published results of a Phase 2b clinical trial. 'The results of this study demonstrate that a peptide-based vaccine designed to induce influenza-specific T cell immunity (in the absence of inducing antibody responses against HA) can provide some protection against influenza.'
November 9, 2015 - PepTCell Limited, trading as SEEK, announces a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), to jointly lead a study(1) of SEEK’s universal flu candidate, FLU-v.
December 1, 2010 - SEEK: PepTcell Changes Name due to New Focus and Success
Flu-v Clinical Trials
Flu-v Influenza vaccine candidate continues to be tested in clinical trials.